Cancer Advisor

Keytruda - $29.5 billion Darzalex - $9 billion Opdivo - $7 billion Imbruvica - $5billion Tagrisso - $5 billion Revlimid - $4 billion Verzenio - $4 billion Imfinzi - $4 billion Ibrance - $3 billion Tecentriq - $3 billion In the rapidly evolving field of oncology, several cancer drugs have become best-sellers due to their proven effectiveness against various cancer types. Below, we examine some of the top-selling cancer drugs, highlighting their FDA-approved indications, mechanisms of action, and sales figures. 1. Keytruda (Pembrolizumab) - $29.5 billion Keytruda is the world's bestselling cancer drug by a large margin. (Merck & Co.) Company: Merck & Co. 2024 sales: $29.5 billion Indications Approved by FDA: Melanoma,  ( KEYNOTE-006 and KEYNOTE-054 trials) Non-small cell lung cancer,  ( KEYNOTE-010, KEYNOTE-407, KEYNOTE-189, KEYNOTE 671 trials) head and neck cancer,  ( KEYNOTE-012 and KEYNOTE-048) kidney cancer (renal cell carcinoma),  ( KEYNOTE-426) classical ...

Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...